|
Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC). |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Janssen |
|
|
Employment - JC Wilson/Research Trajectory; Ontada/McKesson |
Leadership - JC Wilson/Research Trajectory |
Stock and Other Ownership Interests - McKesson |
|
|
Employment - Ontada/McKesson |
|
|
Employment - Ontada/McKesson |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - McKesson; Moderna Therapeutics; Oncolytics (I) |
Honoraria - Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - Advi; Boehringer Ingelheim; Bristol-Myers Squibb; New Century Health |